Tardive drug-induced extrapyramidal syndromes

Pharmacopsychiatry

Volumn 33, Issue SUPPL. 1, 2000, Pages 14-33

  Marsalek, M ^a  

^a Mental Hospital Prague Bohnice   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; ANTIOXIDANT; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLONIDINE; CLOZAPINE; NEUROLEPTIC AGENT; NIFEDIPINE; OLANZAPINE; PHENYTOIN; PROFENAMINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; TETRABENAZINE; TRIHEXYPHENIDYL;

AKATHISIA; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG EFFECT; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; GILLES DE LA TOURETTE SYNDROME; HIGH RISK POPULATION; HUMAN; MYOCLONUS; PARKINSONISM; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; TARDIVE DYSKINESIA;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CHOLINERGIC ANTAGONISTS; DIAGNOSIS, DIFFERENTIAL; DOPAMINE; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED;

EID: 0033790722     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-7672     Document Type: Review

References (232)

1. Temporary remission of tardive dystonia following electroconvulsive therapy
2. Non-functional CYP2D5 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients
3. Neurological syndromes associated with antipsychotic drug use
4. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype
5. Persistent drug-induced parkinsonism
6. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia
7. A survey of tardive dyskinesia in psychiatric outpatients
8. Substance abuse as a risk factor for tardive dyskinesia: A retrospective analysis of 1,027 patients
9. Tardive dyskinesia
10. Akathisia variants and tardive dyskinesia
11. Tardive dyskinesia: A 3-year follow-up study
12. Predictors of the course of tardive dyskinesia in patients receiving neuroleptics
13. Tardive tourettism after exposure to neuroleptic therapy
14. Clonazepam and phenobarbital in tardive dyskinesia
15. Selective peripheral denervation for the treatment of spasmodic torticollis
16. Clinical characteristics of akathisia: A systematic investigation of acute psychiatric inpatient admission
17. Pseudoakathisia and schizophrenic negative symptoms
18. Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia
19. Tardive akathisia
20. Tardive dystonia: Late-onset and persistent dystonia caused by antipsychotic drugs
21. Tardive akathisia: An analysis of clinical features and response to open therapeutic trial
22. Free radicals and tardive dyskinesia
23. The trial use of clozapine for abnormal involuntary movement disorders
24. Subjective awareness of abnormal involuntary movements in chronic schizophrenic patients
25. Paradoxical response to dopamine agonists in tardive dyskinesia
26. Spontaneous and tardive dyskinesias: Clinical and laboratory studies
27. Affective disorder and tardive dyskinesia
28. Clozapine: Neuroleptic-induced EPS and tardive dyskinesia
29. Pharmacological characterization of tardive dyskinesia
30. Tardive dyskinesia: Outcome at 10 years
31. Spontaneous dyskinesia
32. Tardive dyskinesia as a life-threatening illness
33. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia
34. Tardive dystonia and diffuse idiopathic skeletal hyperostosis
35. Effects of risperidone in tardive dyskinesia: An analysis of the Canadian Multicentre Risperidone Study
36. Factors related to tardive dyskinesia
37. Tardive dyskinesia in a nonpsychiatric patient due to short-term use of a neuroleptic/anticholinergic combination drug
38. A five year follow-up study of tardive dyskinesia
39. A 5-year prospective longitudinal study of tardive dyskinesia: Factors predicting appearance of new cases
40. Prevalence and severity of akathisia in patients on clozapine
41. Early dyskinesia - Vulnerability
42. Persistence of neurological symptoms due to neuroleptic
43. Persistent dyskinesia
44. Motor disorders induced by neuroleptics. (A proposal new classification)
45. Clozapine-related tardive dyskinesia
46. Disappearance of akathisia following electroconvulsive treatment
47. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients
48. Treatment of tardive dyskinesia
49. CNS consequences of psychotropic drug withdrawal in autistic children: A follow-up report
50. The emerging role of clozapine in the treatment of movement disorders
51. High-dose anticholinergic therapy in dystonia
52. A therapeutic approach to tardive dyskinesia
53. Definition and classification of myoclonus
54. Clinical research techniques in tardive dyskinesia
55. Neurological symptoms in pharmacotherapy of psychoses
56. Progress in the treatment of tardive dyskinesia: Theory and practice
57. Neurobiological substances of tardive dyskinesia: The GABA hypothesis
58. Tardive oculogyric crises
59. The effect of activation procedures on neuroleptic-induced akathisia
60. Tardive dystonia in a psychiatric hospital
61. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism, and hyperkinesia
62. Postural myoclonus associated with long-term administration of neuroleptics in schizophrenic patients
63. Tardive dyskinesia and diabetes mellitus
64. A case of withdrawal dyskinesia
65. Tardive dyskinesia and anticholinergics drugs
66. The evaluation and treatment of neuroleptic-induced movement disorders
67. Tardive dyskinesia and affective disorder
68. Drug variables in the etiology of tardive dyskinesia: Application of discriminant function analysis
69. Comparison of severe and mild tardive dyskinesia: Implication for etiology
70. Clinical forms of severe tardive dyskinesias
71. The natural history of tardive dyskinesia
72. Ten-year outcome of tardive dyskinesia
73. Relationship between tardive dyskinesia, L-dopa-induced hyperkinesia and parkinsonism
74. Tardive dyskinesia
75. Intolerance to neuroleptic drugs: The art of avoiding extrapyramidal syndromes
76. Clozapine and haloperidol in a single-blind crossover trial: Therapeutic and biochemical aspects in the treatment of schizophrenia
77. The clinical phenomenon of akathisia
78. Tardive dystonia and severe dyskinesia
79. Heterogeneity of tardive dyskinesia: A multivariate analysis
80. Predicting the longterm risk of tardive dyskinesia in outpatients maintained on neuroleptic medications
81. Persistent phenothiazine dyskinesia treated with tetrabenazine
82. Differential diagnosis of tardive dyskinesia: An overview
83. Tardive dystonia
84. Effect of anticholinergics on tardive dyskinesia: A controlled discontinuation study
85. Topographic subtypes of tardive dyskinesia in schizophrenic patients less than 60 years of age
86. The significance of subtyping tardive dyskinesia: A study of prevalence and associated factors
87. Cortical reflex myoclonus
88. Akathisia: Prevalence and associated dysphoria in an in-patient population with chronic schizophrenia
89. Tongue, arms, face movement enough to assess dyskinesia
90. An unusual effect of ECT on drug-induced parkinsonism and tardive dystonia
91. Drug-induced parkinsonism
92. ECT and tardive dyskinesia
93. Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia
94. A case of tardive akathisia
95. A statistical trial of subclassification for tardive dyskinesia
96. Clozapine in tardive Tourette syndrome
97. In search of treatment for tardive dyskinesia: Review of the literature
98. Changing epidemiology of tardive dyskinesia: An overview
99. Tardive dyskinesia - Reversible and persistent
100. Pharmacological treatments of tardive dyskinesia in the 1980s
101. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients
102. Subchronic administration of piracetam in tardive dyskinesia - Placebo controlled cross-over comparison
103. Atypical variants of tardive dyskinesia, treated by a combination of clozapine with propranolol and clozapine with tetrabenazine
104. Tardive dyskinesia. Prevalence and risk factors, 1959-1979
105. The prevalence of presumed tardive dyskinesia in psychiatric in-patients and outpatients
106. Integrating incidence and prevalence of tardive dyskinesia
107. Tardive dyskinesia: Prevalence, incidence, and risk factors
108. Natural history and treatment of tardive dystonia
109. A case of Tourette syndrome developing during haloperidol treatment
110. A comparison of two iatrogenic dyskinesias
111. Noradrenergic and neuroradiological abnormalities in tardive dyskinesia
112. Treatment of tardive dyskinesia: I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine
113. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine
114. Drug-induced dystonia tarda - Treatment with L-dopa
115. Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects
116. Sub-syndromes of tardive dyskinesia
117. The pharmacology of tardive dyskinesia
118. Prolonged drug-induced parkinsonism
119. Gilles de la Tourette syndrome after long term chlorpromazine therapy
120. The reversibility of 'permanent' tardive dyskinesia
121. Drug-induced myoclonus
122. The Shanghai 800: Prevalence of tardive dyskinesia in a chinese psychiatric hospital
123. Drug therapy of tardive dyskinesia
124. Persistent muscular restlessness after phenothiazine treatment: Report of three cases
125. Mortality and tardive dyskinesia
126. A case of tardive Tourette-like syndrome
127. Extrapyramidal side-effects of clozapine and haloperidol
128. Prosthodontic implications of tardive dyskinesia
129. Fatal myoglobinuric renal failure in a patient with tardive dyskinesia
130. Pharmacological studies of tardive dyskinesia
131. Pharmacological characterization of tardive dyskinesia
132. The effect of clozapine on tardive dyskinesia
133. Tardive myoclonus
134. Pharmacotherapeutic trials in tardive dyskinesia
135. The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy
136. Do antidepressants increase risk of suicide?
137. Subtypes of tardive dyskinesia
138. Mortality and facial dyskinesia
139. The nisthsdale schizophrenia surveys. IX. Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels
140. Treatment of the neuroleptic-nonresponsive schizophrenic patient
141. Neurologic approach to drug-induced movement disorders: A study of 125 patients
142. Identification of a tardive dyskinesia patients by pharmacologic probes
143. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications
144. Predictors of tardive dyskinesia: Results of a cross-sectional study in an outpatients population
145. Tourette-like syndrome after long-term neuroleptic treatment
146. Diabetes mellitus and tardive dyskinesia
147. Tardive dyskinesia and glucose metabolism
148. Persistent tardive dyskinesia in bipolar patients
149. Asymmetry of abnormal involuntary movements: A prevalence study
150. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia - A retrospective study of 387 patients
151. Parkinsonism following neuroleptic withdrawal
152. Tardive dyskinesia in psychiatric patients with substance use disorders
153. Severe degenerative changes of the temporomandibular joint secondary to the effects of tardive dyskinesia: A literature review and case report
154. Spontaneous involuntary disorders of movement
155. Human gene for torsion dystonia located on chromosome 9q32-34
156. Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: A prospective longitudinal study
157. Neurological consequences of psychotropic drug withdrawal in schizophrenic children
158. Electroconvulsive therapy in tardive dystonia
159. Tolerability and therapeutic effect of clozapine
160. Tardive dyskinesia: Are first signs reversible?
161. Tardive dystonia: Prevalence, risk factors, and comparison with tardive dyskinesia in a population of 200 acute psychiatric inpatients
162. The prevalence of tardive dyskinesia in a mentally retarded population
163. The plasma phenylalanine/large neutral amino acid ratio: A risk factor for tardive dyskinesia
164. Acute generalized myoclonus following buspirone administration
165. The prevalence of tardive dystonia in patients with chronic schizophrenia
166. Clinical characteristics of 15 patients with tardive dystonia
167. Intravenous challenges of benztropine and propranolol in tardive akathisia
168. Negative symptoms, cognitive dysfunction, tardive akathisia and tardive dyskinesia
169. Akathisia and clozapine treatment
170. Irreversible drug induced parkinsonism
171. Clozapine-induced myoclonus and generalized seizures
172. Prospective study of tardive dyskinesia in the elderly
173. Successful treatment of respiratory dyskinesia with picoTesla range magnetic fields
174. Serotonin in involuntary movement disorders
175. Persistent dyskinesias following phenothiazine treatment
176. Ein eigentumliches syndrom im oralen bereich bei megaphenapplikation
177. Research diagnoses for tardive dyskinesia
178. Treatment of tardive dyskinesia with propranolol
179. Impaired glucose tolerance and abnormal movements in patients with schizophrenia
180. Tardive dyskinesia with Tourette-like syndrome
181. Prevalence of dystonia in veterans on chronic antipsychotic therapy
182. Quatre cas de dyskinesie facio-bucco-linguo-masticatice a evolution prolongee secondaire a un traitement par les neuroleptiques
183. Phenothiazine-produced extra-pyramidal system disturbance
184. Clozapine in tardive dyskinesia
185. Diazepam-induced changes in tardive dyskinesia: Suggestion for a new conceptual model
186. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity and treatment-resistant psychosis
187. Drug history and tardive dyskinesia
188. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients
189. Tardive tremor
190. Tardive Tourette syndrome in an autistic patient after long term neuroleptic administration
191. Tardive tremor
192. Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life
193. Rib fractures as an unusual complication of severe tardive dystonia
194. Clozapine in tardive dyskinesia: Observations from human and animal model studies
195. An open-label study of botulinum toxin A for treatment of tardive dystonia
196. Clonazepam treatment of tardive dyskinesia: A practical GABAmimetic strategy
197. Tardive dyskinesia in the aged. Duration of treatment relationship
198. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
199. Tardive myoclonus
200. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia: The Curacao Extrapyramidal Syndromes Study I
201. The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: The Curacao Extrapyramidal Syndromes Study II
202. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III
203. Tardive dyskinesia: Who is at risk?
204. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality
205. Schizophrenia, long-term neuroleptic treatment and mechanism of late-onset side effects
206. Cognitive dysfunction in schizophrenia followed up over 5 years, and its longitudinal relationship to the emergence of tardive dyskinesia
207. Bilateral posteroventral pallidotomy for severe antipsychotic induced tardive dyskinesia and dystonia
208. Schizophrenics with tardive dyskinesia - Neuropsychological deficit and family psychopathology
209. Tardive akathisia
210. Relation between elderly and AIDS patients with drug-induced Parkinson's disease
211. Neurochemistry of withdrawal emergent symptoms in children
212. A review of 32 cases of tardive dystonia
213. Tardive dystonia: Four case histories
214. Follow-up study of 11 patients with potentially reversible tardive dyskinesia
215. Functional impairment in tardive dyskinesia: Medical and psychosocial dimensions
216. Other factors in the development of tardive dyskinesia
217. Familial tardive dyskinesia
218. Gender as a factor in the development of tardive dyskinesia
219. The complications of tardive dyskinesia
220. Incidence of tardive dyskinesia in an outpatients population
221. Anticholinergic drugs as factors in the development of tardive dyskinesia
222. Prevalence of tardive dystonia
223. Early versus late onset psychosis and tardive dyskinesia
224. A comparison of severe tardive dystonia and severe tardive dyskinesia
225. Factors in the development of severe forms of tardive dyskinesia
226. Spontaneous improvement of tardive dystonia during mania
227. Mortality and morbidity in tardive dyskinesia: Association in chronic schizophrenia